Medullary Thyroid Carcinoma Clinical Trial
Official title:
A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)
| Verified date | November 2018 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Background:
- The combination of anti-cancer drugs vandetanib (given orally) and bortezomib (given
intravenously) has not been used in humans. However, both drugs have been studied
separately. Bortezomib has been approved by the U.S. Food and Drug Administration (FDA)
for treating multiple myeloma and mantle cell lymphoma, while vandetanib is still under
investigation pending FDA approval.
- Both bortezomib and vandetanib are under investigation for use in treating certain kinds
of cancer. Researchers hope that the combination of these two drugs will be more
effective than either of them alone.
Objectives:
- To determine if the combination of vandetanib and bortezomib will decrease the amount of
the cancer and, if it does, to determine how long the response will last.
- To determine any side effects that may occur with this combination of treatments.
- To determine what doses of each drug are well tolerated and safe when given together.
- To study genetic mutations in tumors to better understand how tumors grow and how these
drugs interact with the tumor.
Eligibility:
- Patients 18 years of age and older with solid tumors that cannot be surgically removed
and have either recurred or shown further growth. The tumor(s) must be able to be
evaluated by X-ray, MRI (magnetic resonance imaging), and CT (computerized tomography)
scanning.
- Patients who have been diagnosed with medullary thyroid cancer will participate in Phase
II of the study.
Design:
- Tumor samples may be taken at the start of the study for research purposes.
- Phase I: Patient groups will be treated on an outpatient basis with vandetanib and
bortezomib, given at increasing doses over four different levels to determine the
maximum tolerated dose calculated by height and weight:
- Doses will be given on Days 1, 4, 8, and 11 for each 28-day cycle.
- Two additional levels (Level 1A and Level 1B) may be included in the study, depending on
side effects at various levels.
- Phase II: Patients with medullary thyroid cancer will be divided into two groups, with
two patients in Group A for every one patient in Group B. No placebo will be involved in
this study.
- Group A: Patients will be treated with vandetanib and bortezomib at the maximally
tolerated dose of the Phase I study.
- Group B: Patients will be treated with bortezomib alone.
- A second tumor sample may be taken. In patients with thyroid cancer, the second biopsy
will be done at the 6-week evaluation (approximately 42 days after beginning). In
patients with cancer other than thyroid cancer, the second biopsy will be obtained on
Day 4 of either the first or second cycle, after the bortezomib infusion.
- The effects of the drugs will be studied through blood samples and CT scans taken during
and after various drug cycles.
| Status | Terminated |
| Enrollment | 22 |
| Est. completion date | December 9, 2016 |
| Est. primary completion date | April 1, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility |
-INCLUSION CRITERIA: 1. Pathologic confirmation of cancer by the Laboratory of Pathology, National Cancer Institute (NCI) 2. Phase I: Diagnosis of recurrent, metastatic or primary unresectable solid tumor that does not have curative standard treatment. Phase II: Diagnosis of recurrent, metastatic or primary unresectable medullary thyroid cancer (MTC). 3. Measurable disease at presentation: Either by Response Evaluation Criteria in Solid Tumors (RECIST) or by measurement of serum markers (calcitonin, carcinoembryonic antigen (CEA), prostate specific antigen (PSA) or cancer antigen 125 or carbohydrate antigen 125 (CA-125) in the dose-finding portion of the study; with disease measurable by RECIST required only in the phase II cohort. 4. A life expectancy of at least 3 months and Eastern Cooperative Oncology Group (ECOG) performance status 0 1. 5. Age greater than or equal to 18 years 6. Last dose of chemotherapy or experimental therapy more than 4 weeks (6 weeks in the case of nitrosourea) prior to enrollment date; unless the last therapy consisted of an oral agent whose average half life is known to be less than 48 hours in which case only 2 weeks need to have elapsed. Regardless of the therapy, any toxicity greater than Common Terminology Criteria in Adverse Events (CTCAE) grade 1 from previous anti-cancer therapy must have been resolved. 7. Last radiotherapy treatment 4 weeks prior to starting treatment with this protocol with the exception of palliative radiotherapy and there must be sites of measurable disease that did not receive radiation. 8. Organ and marrow function as defined: - total bilirubin less than 1.5 times the upper limit of reference range (ULRR), unless the patient meets the criteria for Gilbert's Syndrome - alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) all three less than 2.5 times the upper limit of the reference range (ULRR), or less than 5 times the ULRR if judged by the investigator to be related to liver metastases - serum creatinine less than 1.5 times the ULRR or creatinine clearance greater than or equal to 30 mL/minute (calculated by Cockcroft-Gault formula or measured in a timed urine collection) - serum calcium below the CTCAE grade 1 upper limit (11.5mg/dL or 2.9 mmol/L). In cases where the serum calcium is below the normal range, the calcium adjusted for albumin is calculated and substituted for the measured value. - serum potassium greater than the lower limit of normal (LLN) and less than 5.5 mmol/L. - serum magnesium greater than the LLN and less than 3.0 mg/dL or 1.23 mmol/L. - absolute neutrophil count greater than or equal to 1000/mm(3) - platelet count greater than or equal to 100,000/mm(3) - Prothrombin time (PT) less than or equal to 4 seconds above ULN and partial thromboplastin time (PTT) less than or equal to 10 seconds above ULN. 9. Ability to understand and sign an informed consent document. 10. Provision of informed consent prior to any study-related procedures 11. Negative pregnancy test for women of childbearing potential 12. Ability and willingness to follow the guidelines of the clinical protocol including visits to National Cancer Institute (NCI), Bethesda, Maryland for treatment and follow up visits. 13. Because the effects of chemotherapy on the developing human fetus are potentially harmful, female patients must be one year post-menopausal, surgically sterile, or using an acceptable method of contraception during and continued after the last dose of study medications (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation). Male patients must be surgically sterile or using an acceptable method of contraception during their participation in this study. Contraceptive use will continue for at least four months after the last dose of study medication. EXCLUSION CRITERIA: 1. Patients with cancer potentially curable by surgical excision alone or patients who have not received therapy that might be considered standard and potentially curable. 2. Evidence of severe or uncontrolled systemic disease or any concurrent condition including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, unstable hypertension, seizure disorder, or psychiatric illness which in the Investigators opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol. 3. Untreated brain metastases (or local treatment of brain metastases within the last 6 months) due to the poor prognosis of these patients and difficulty ascertaining the cause of neurologic toxicities. 4. During Phase II enrollment: Prior therapy with vandetanib. 5. Women who are currently pregnant or breast-feeding, due to the possible adverse effects on the developing fetus and infants. 6. The presence of a second malignancy within the last 2 years, other than squamous cell carcinoma of the skin or in situ cervical cancer because it will complicate the primary objective of the study. Cancer survivors who have been free of disease for at least two years can be enrolled in this study. - There is one other exception to the exclusion of secondary malignancies: multiple endocrine neoplasia type 2 (MEN2) patients with concurrent medullary thyroid cancer and pheochromocytoma may be enrolled at the discretion of the Principal Investigator. 7. Patients with evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement. 8. Any unresolved toxicity greater than CTCAE grade 1 (except alopecia) from previous anticancer therapy. Patients with grade 1 neuropathy will be evaluated on a case by case basis for entry into study. Baseline conditions will be taken into consideration. 9. Major surgery within 4 weeks, or incompletely healed surgical incision before starting study therapy. 10. Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease greater than or equal to 2 within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia. 11. History of arrhythmia (multifocal premature ventricular contractions PVCs, bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation controlled on medication is not excluded. 12. History (within the last 6 months) or presence of stroke/cerebrovascular accident. 13. Corrected QT interval (QTc) prolongation with other medications. If the medication can be discontinued and an alternative medication started that does not cause QTc prolongation, the patient would be eligible. If no alternative medication is available and the medication cannot be discontinued for medical reasons, then the patient would not be eligible. 14. Congenital long Q wave, T wave (QT) syndrome, or 1st degree relative with unexplained sudden death under 40 years of age. 15. Presence of left bundle branch block (LBBB). 16. QTc with Bazett's correction that is not measurable, or greater than or equal to 480 msec on screening electrocardiogram (ECG). (Note: If a patient has a QTc interval greater than or equal to 480 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be less than 480 msec in order for the patient to be eligible for the study). Patients who are receiving a drug that has a risk of QTc prolongation are excluded if QTc is greater than or equal to 460 msec. 17. Concurrent medication that may cause QTc prolongation or induce Torsades de Pointes: Those medications in Group One will not be allowed. Those medications in Group Two will be allowed. 18. Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg) 19. Currently active (uncontrolled) diarrhea greater than or equal to CTCAE Grade 2 that may affect the ability of the patient to absorb the vandetanib or tolerate diarrhea. Antidiarrhea medications are allowed in patients with chronic diarrhea. 20. Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of cytochrome P450 3A4 (CYP3A4) function. 21. Major surgery within 4-weeks, or incompletely healed surgical incision before starting study medications. Biopsies, port placements, and dental work are examples of acceptable (nonmajor) surgery within the 4 week time frame. 22. Inability to take oral medications for whatever reason. |
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Cancer Institute (NCI) |
United States,
Abstract: Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. A. W. Gramza, S. A. Wells, S. Balasubramaniam, and A. T. Fojo Journal of Clinical Oncology 2011 29:15_suppl, 5
Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006 Jan;16(1):47-53. — View Citation
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006 May 10;295(18):2164-7. — View Citation
Truong T, Rougier Y, Dubourdieu D, Guihenneuc-Jouyaux C, Orsi L, Hémon D, Guénel P. Time trends and geographic variations for thyroid cancer in New Caledonia, a very high incidence area (1985-1999). Eur J Cancer Prev. 2007 Feb;16(1):62-70. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Phase I: Maximum Tolerated Dose (MTD) of Daily Oral Vandetanib | A maximum tolerated dose for vandetanib will be determined if dose limiting toxicity is observed in 2 or more patients at one of the dose levels being evaluated. The MTD will be the dose level immediately preceding the dose level at which DLT (e.g. defined as neutrophil count below 1000/ µL (grade 3) on 2 consecutive measurements drawn at least 72 hours OR a single neutrophil count below 500/µL occurred. Platelet count below 50,000 µL (grade 3) on 2 consecutive measurements drawn at least 72 hours apart OR a singe platelet count below 25,000/µL. A platelet transfusion administered when platelet count is below 50,000/µL is dose limiting thrombocytopenia, unless the transfusion is being administered for peri-operative coverage. | 80 days | |
| Primary | Phase I: Maximum Tolerated Dose (MTD) of Daily Oral Bortezomib | A maximum tolerated dose for bortezomib will be determined if dose limiting toxicity is observed in 2 or more patients at one of the dose levels being evaluated. The MTD will be the dose level immediately preceding the dose level at which DLT (e.g. defined as neutrophil count below 1000/ µL (grade 3) on 2 consecutive measurements drawn at least 72 hours OR a single neutrophil count below 500/µL occurred. Platelet count below 50,000 µL (grade 3) on 2 consecutive measurements drawn at least 72 hours apart OR a singe platelet count below 25,000/µL. A platelet transfusion administered when platelet count is below 50,000/µL is dose limiting thrombocytopenia, unless the transfusion is being administered for peri-operative coverage. | 80 days | |
| Primary | Phase 2: Tumor Response in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib | Response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. | 4 months | |
| Primary | Phase 2: Progression Free Survival in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib | Progression free survival is defined as the duration of time from start of treatment to time of progression. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as the appearance of one or more new lesions or unequivocal progression of existing non-target lesions. Although a clear progression of "non-target" lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator). | 4 months | |
| Secondary | Response Rate (Complete Response (CR) + Partial Response (PR) of Adults With a Diagnosis of MTC Treated With Either of Two Regimens: (1) Daily Oral Vandetanib and Bortezomib or (2) Daily Oral Vandetanib | Comparison of response between cohorts 1, 2A and 2B was to be determined by computed tomography scan reviews using the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. | 2-3 years | |
| Secondary | Progression Free Survival (PFS) | Progression free survival is defined as the duration of time from start of treatment to time of progression. Comparison of PFS between cohorts 1, 2A and 2B was to be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progressive disease is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. | 2-3 years | |
| Secondary | Number of Participants With Adverse Events | Here is the number of participants with adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0. For the detailed list of adverse events see the adverse event module. | Date treatment consent signed to date off study, approximately 7 years and 9 days | |
| Secondary | Number of Participants With Tumor Biomarker Calcitonin (CTN) Response | Calcitonin was measured by the biomarker response criteria. Complete response (CR) is normalization (= upper limit of normal) of CTN level following treatment, confirmed with a repeat CTN level at least 4 weeks apart. Partial response (PR) is a =50% decrease in the CTN level relative to the baseline level, confirmed with a repeat CTN level at least 4 weeks apart. Progressive disease is a =50% increase in the CTN relative to the baseline level, confirmed with a repeat CTN level at least 4 weeks apart. Stable disease is <50% increase or decrease in CTN level relative to the baseline level. | 4 weeks | |
| Secondary | Number of Participants With Tumor Biomarker Carcinoembryonic Antigen (CEA) Response | Carcinoembryonic Antigen (CEA) was measured by the biomarker response criteria. Complete response (CR) is normalization (= upper limit of normal) of CEA level following treatment, confirmed with a repeat CEA level at least 4 weeks apart. Partial response (PR) is a =50% decrease in the CEA level relative to the baseline level, confirmed with a repeat CEA level at least 4 weeks apart. Progressive disease is a =50% increase in the CEA relative to the baseline level, confirmed with a repeat CEA level at least 4 weeks apart. Stable disease is <50% increase or decrease in CEA level relative to the baseline level. | 4 weeks | |
| Secondary | Percentage of Participants With a Change in Frequency in Tumor-Related Diarrhea Compared to Baseline | Complete response is an average of 0-2 formed stools per day for a period of at least 4 weeks. partial response is a =50% decrease in the average stool frequency relative to baseline and a change in stool consistency from watery to loose (partially formed) for a period of at least 4 weeks. No response is criteria for CR or PR not met. Only patients with a stool frequency of =5/day and a stool consistency of watery will be evaluable for clinical response. | Baseline, and for a period of at least 4 weeks post study drug administration | |
| Secondary | Percentage of Participants With a Change in Consistency in Tumor-Related Diarrhea Compared to Baseline | Baseline stool consistency (formed, loose or partially formed, watery) will be the consistency most frequently observed during a 7-day period immediately prior to starting vandetanib. Complete response (CR) is an average of 0-2 formed stools per day for a period of at least 4 weeks. Partial response (PR) is a =50% decrease in the average stool frequency relative to baseline and a change in stool consistency from watery to loose (partially formed) for a period of at least 4 weeks. No response is criteria for CR or PR not met. Only patients with a stool frequency of =5/day and a stool consistency of watery will be evaluable for clinical response. | Baseline, and for a period of at least 4 weeks post study drug administration | |
| Secondary | Maximum Bortezomib Plasma Concentration Normalized to Dose (Cmax/D) | Geometric mean for Bortezomib pharmacokinetic (PK) parameters both before (cycle 1 day 1) and during steady-state Vandetanib (cycle 3 day 1; exposures are dose normalized). Bortezomib plasma concentrations were measured using a validated LC-MS/MS assay with a lower limit of quantification (LLOQ) of 1 ng/mL. Only measured concentrations above the LLOQ were used in the calculation of PK parameters. The maximum plasma concentration (Cmax) was recorded as observed values. | Cycle 1 day 1, and cycle 3 day 1 (an average of 61 days); and Pre-dose, 1, 2,4, 6, 8, 10 and 24 hours post dose | |
| Secondary | Area Under the Bortezomib Plasma Concentration Versus Time Curve From Time Zero to Infinity/Dose (AUCinf/D) | The area under the concentration-time curve (AUC) extrapolated to infinity (AUCinf) was calculated using the linear up-log down trapezoidal method via extrapolation of AUC(LAST) (AUC to the last quantifiable time point) by dividing C(LAST) (the last measurable drug concentration, typically at 24 hour post-dose) by the rate constant of the terminal phase, lambda z. This constant was determined from the slope of the terminal phase of the concentration-time curve using weighted least-squares as the estimation procedure. | Cycle 1 day 1, and cycle 3 day 1 (an average of 61 days); and Pre-dose and 1, 2, 4, 6, 8, 10, and 24 hours post dose | |
| Secondary | Terminal Half-Life (T1/2) of Bortezomib | The time it takes for the measured concentration of the drug to drop by half. | Cycle 1 day 1, and cycle 3 day 1 (an average of 61 days); and Pre-dose and 1, 2, 4, 6, 8, 10, and 24 hours post dose | |
| Secondary | Total Systemic Clearance (CL) of Bortezomib | Total systemic clearance = dose/area under curve extrapolated to infinity (AUCinf.). This measurement represents the rate at which plasma is systematically cleared of drug. | Cycle 1 day 1, and cycle 3 day 1 (an average of 61 days); and Pre-dose and 1, 2, 4, 6, 8, 10, and 24 hours post dose | |
| Secondary | Bortezomib Volume of Distribution (Vss) | Vss represents the volume into which the drug distributes into once given to the patient at steady-state. This volume parameter provides a measure of where in the body the drug is going, based on fluid volume. | Cycle 1 day 1, and cycle 3 day 1 (an average of 61 days); and Pre-dose and 1, 2, 4, 6, 8, 10, and 24 hours post dose | |
| Secondary | Comparison of Steady State Vandetanib Exposure With Relevant Literature Values | Because vandetanib PK exposure was only measured during a single 8-hr window during daily dosing, the only comparison to assess the effect of bortezomib is to compare these values to published literature." | Cycle 3 day 1 (an average of 60 days); and Pre-dose and 1, 2, 4, 6, 8, 10, and 24 hours post dose |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03636945 -
Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma
|
N/A | |
| Withdrawn |
NCT01736878 -
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
|
Phase 2 | |
| Completed |
NCT06067594 -
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
|
||
| Active, not recruiting |
NCT04970134 -
Spanish Study for Molecular Characterization of Thyroid Carcinoma
|
||
| Completed |
NCT01424878 -
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
|
||
| Completed |
NCT02586350 -
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
|
Phase 2/Phase 3 | |
| Completed |
NCT00514046 -
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04787328 -
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
|
Phase 2 | |
| Completed |
NCT01730638 -
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT01511393 -
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
|
||
| Completed |
NCT00880503 -
Collection of Tissue Samples for Study of Multidrug Resistance
|
||
| Not yet recruiting |
NCT06121271 -
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
|
Phase 2 | |
| Completed |
NCT03246659 -
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC
|
Phase 1 | |
| Recruiting |
NCT05534594 -
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
|
N/A | |
| Not yet recruiting |
NCT01373736 -
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
|
Phase 3 |